increased heart rate tirzepatide Cardiovascular effects of Tirzepatide, a dual GIP/GLP1-receptor co-agonist

Brain-derived neurotrophic factor and glucocorticoids: Reciprocal influence on the central nervous system

There is a shifting trend in the risk factors associated with heart failure in epidemiological studies from classic smoking and hypertension as risk factors for ischemic heart disease and heart failure with reduced ejection fraction, to morbid obesity, diabetes mellitus, and metabolic syndrome in the aging population as risk factors for heart failure with preserved ejection failure [5]

Patients should disclose any medical history to their provider and monitor for rare but serious reactions like pancreatitis or thyroid concernsthe same precautions apply to all GLP-1 therapy

The first RCT to investigate the effect of liraglutide in patients with NAFLD was the LEAN study, in which 52 patients with NASH were randomized to either 48 weeks of treatment with liraglutide (1.8 mg/day) or placebo (66)

Its a pipe dream